Surface Strong Positive-charged Nanocomplex formed by Biodegradable materials with DMF number provider



ASD141, an innate checkpoint inhibitor, modulates tumor associated myeloid cells through CD11b and enhances current immune checkpoint blockade in preclinical model.


Partner of choice for novel immunotherapeutics

Ascendo Biotechnology is a strategic partner of choice for novel immunotherapies which exploit the interplay between the innate and adaptive immune response. We are currently seeking partners to accelerate the development and commercialization of our lead oncology drug, ASD141.

If you’re interested in discussing our programmes, please get in touch

Contact Us